Rapid flu test

Bordetellabacillus pertussisBordetella holmesii

World's first fully automated PCR test for the detection of B. pertussis, B. parapertussis, B. holmesii The Vivalytic test is the world's first PCR test for near-patient testing to specifically detect all three whooping cough pathogens: B. pertussis, B. parapertussis, B. holmesii Pathogen differentation is crucial for targeted antibiotic treatment in the early, still unspecific stage of the disease and for controlling the spread of infection Pertussis infection rates 2024 at highest level in recent years with a high hospitalization rate in newborns and the elderly Waiblingen – Bosch Healthcare Solutions (BHCS) has introduced a new PCR test Vivalytic Bordetella, expanding the Vivalytic analysis platform’s capabilities to include whooping cough. This test can specifically detect the three major whooping cough pathogens Bordetella pertussis, B. parapertussis, and B. holmesii in under an hour. BHCS is expanding its test portfolio for “respiratory diseases” to include “pertussis” diagnosis, just in time for the upcoming cold and flu season. The triple test, unique in its composition of pathogens, allows for rapid diagnosis in local healthcare facilities. Previously, such pathogens were only detectable in larger test panels. “Vivalytic Bordetella is our response to the rising number of pertussis cases in Germany. Pertussis poses a significant risk, particularly to infants, the elderly, and individuals with pre-existing health conditions, necessitating rapid diagnosis,” says Marc Meier, president of Bosch Healthcare Solutions. Whereas PCR testing in a central laboratory requires one day and culture detection takes three to seven days1,